TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Misses Expectations By $0.01 EPS

TuHURA Biosciences (NASDAQ:HURA) issued its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01), Zacks reports.

TuHURA Biosciences Stock Performance

NASDAQ HURA opened at $1.62 on Thursday. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $4.44. The company has a market capitalization of $98.37 million, a P/E ratio of -2.57 and a beta of -0.32. The company has a fifty day moving average of $1.36 and a 200-day moving average of $1.64.

Analysts Set New Price Targets

HURA has been the topic of a number of research analyst reports. Wall Street Zen upgraded TuHURA Biosciences from a “sell” rating to a “hold” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in TuHURA Biosciences by 1.6% during the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock worth $5,629,000 after purchasing an additional 35,426 shares during the last quarter. Geode Capital Management LLC increased its position in shares of TuHURA Biosciences by 6.4% during the 4th quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock valued at $501,000 after purchasing an additional 39,710 shares during the last quarter. State Street Corp increased its position in shares of TuHURA Biosciences by 4.9% during the 4th quarter. State Street Corp now owns 289,133 shares of the company’s stock valued at $219,000 after purchasing an additional 13,594 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of TuHURA Biosciences by 209.8% during the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after buying an additional 54,051 shares in the last quarter. Finally, Barclays PLC raised its holdings in shares of TuHURA Biosciences by 42.6% during the 4th quarter. Barclays PLC now owns 52,615 shares of the company’s stock valued at $40,000 after buying an additional 15,725 shares in the last quarter. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.